Table 2 Univariate meta-regression analysis for the effects of n-3 PUFA on joint pain in patients with OA

Patient number

− 0.0001 to 0.0007

0.16

Mean age (years)

− 0.012 to 0.073

0.13

Men (%)

− 0.0117 to 0.0301

0.33

n-3 PUFA dose (mg/d)

− 0.0006 to 0.0002

0.21

EPA dose (mg/d)

− 0.0012 to 0.0014

0.82

DHA dose (mg/d)

− 0.0007 to 0.0001

0.18

Follow-up duration (months)

− 0.003 to 0.013

0.18